Adnan Mahmood, DO
Neurology · Avondale, AZNPI 1528293149
Payments from drug & device makers
Across 456 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$602
- UCB, Inc.$600
- Lundbeck LLC$402
- Supernus Pharmaceuticals, Inc.$357
- Lilly USA, LLC$343
- plus $3K from 35 others
What the payments were for
- Food & beverage$7,10196%
- Education$2594%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 182 | $2,262 |
| Teva Pharmaceuticals USA, Inc. | 29 | $602 |
| UCB, Inc. | 35 | $600 |
| Lundbeck LLC | 19 | $402 |
| Supernus Pharmaceuticals, Inc. | 33 | $357 |
| Lilly USA, LLC | 17 | $343 |
| Novartis | 21 | $294 |
| AstraZeneca | 11 | $292 |
| Pfizer | 13 | $246 |
| SK Life Science, Inc. | 9 | $207 |
| Biogen | 10 | $183 |
| Neurocrine Biosciences, Inc. | 9 | $178 |
| Amneal Pharmaceuticals LLC | 9 | $157 |
| Johnson & Johnson | 1 | $140 |
| EMD Serono, Inc. | 6 | $138 |
| GE HealthCare | 4 | $77 |
| Argenx US, Inc. | 3 | $69 |
| Sumitomo Pharma America, Inc. | 4 | $63 |
| Sunovion Pharmaceuticals Inc. | 3 | $57 |
| Amgen | 2 | $52 |
| Bausch Health US, LLC | 4 | $49 |
| Jazz Pharmaceuticals Inc. | 2 | $49 |
| Corium, LLC | 2 | $46 |
| Acadia Pharmaceuticals Inc | 3 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $44 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Impel Pharmaceuticals Inc. | 2 | $40 |
| Neurelis, Inc. | 1 | $38 |
| Promius Pharma LLC | 2 | $36 |
| Grifols USA, LLC | 2 | $34 |
| Sanofi | 2 | $32 |
| Boston Scientific | 1 | $28 |
| Abbott | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| Aucta Pharmaceuticals, Inc. | 2 | $18 |
| GRT US Holding, Inc. | 1 | $18 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Cala Health, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,360 in reported general payments places this provider in the 55th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $142,343 |
| Emgality PenGalcanezumab-Gnlm | 27 | $20,338 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $20,027 |
| NayzilamMidazolam | 11 | $16,738 |
| RytaryCarbidopa/Levodopa | 18 | $16,339 |
| UbrelvyUbrogepant | 14 | $15,433 |
| Nurtec OdtRimegepant Sulfate | 15 | $14,736 |
| Carbamazepine ErCarbamazepine | 41 | $6,651 |
| Lacosamide | 79 | $6,427 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 229 | $4,577 |
| Memantine Hcl | 136 | $4,433 |
| Levetiracetam | 174 | $4,039 |
| Zolmitriptan | 12 | $4,019 |
| Memantine Hcl ErMemantine Hcl | 41 | $3,518 |
| Pyridostigmine Bromide | 17 | $3,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $34 | $142,34313 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $157 | $19,80935 claims |
| UCB, Inc.Nayzilam | $600 | $16,73811 claims |
| AbbVieUbrelvy | $2,262 | $15,43314 claims |
| PfizerNurtec Odt | $246 | $14,73615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 388 neurology providers in Arizona.
Other neurology in Avondale
- David WeidmanPhoenix$7.4M
- Hemant PandeyChandler$6.2M
- Stephen FlitmanPhoenix$4.4M
- Barry HendinPhoenix$4.4M
- Jeremy ShefnerPhoenix$3M
- Danielle CabralPhoenix$2.8M
- Suraj MuleyPhoenix$2.8M
- Todd SchwedtPhoenix$2.8M
- Todd LevinePhoenix$2.7M
- Nida LaurinScottsdale$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.